CAM
CLDX icon

Close Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Close Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-133
Closed -$3K – 272
2025
Q2 		$3K Hold
133
– – ﹤0.01% 234
2025
Q1 		$2K Hold
133
– – ﹤0.01% 238
2024
Q4 		$3K Hold
133
– – ﹤0.01% 232
2024
Q3 		$5K Hold
133
– – ﹤0.01% 236
2024
Q2 		$5K Hold
133
– – ﹤0.01% 236
2024
Q1 		$6K Hold
133
– – ﹤0.01% 233
2023
Q4 		$5K Hold
133
– – ﹤0.01% 221
2023
Q3 		$4K Buy
+133
New +$4.17K ﹤0.01% 219

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return